Results 211 to 220 of about 296,448 (281)

Associations of Lifestyle‐Related Factors and Psoriatic Arthritis Disease Activity: The Dutch South West Psoriatic Arthritis Study

Arthritis Care &Research, Volume 78, Issue 11, Page 1711-1720, November 2026.
Objective This study aims to investigate lifestyle‐related factors in patients with psoriatic arthritis (PsA) and their association with disease activity measurements. Methods This multicenter cohort included 938 patients who were newly diagnosed with PsA between 2013 and 2023.
Batoul Hojeij, Ilja Tchetverikov, Marc R. Kok, Marijn Vis, Yvonne Goekoop‐Ruiterman, Jessica Bijsterbosch, Paul Baudoin, Reinhard Bos, Jos H. van der Kaap, Petra Kok, Lindy‐Anne Korswagen, Jolanda J. Luime   +11 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, Volume 78, Issue 11, Page 2261-2273, November 2026.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Identifying Systemic Lupus Erythematosus From Serum Proteomic Profiles Using Machine Learning and Genetic Risk Stratification

Arthritis &Rheumatology, Volume 78, Issue 11, Page 2280-2291, November 2026.
Objective Proteome‐wide risk models for lupus remain underexplored. We developed classification models to identify lupus from serum proteomic profiles. Methods Patients with lupus and individuals with other autoimmune diseases in the UK Biobank were included.
Mehmet Hocaoǧlu, Jishnu Das, Amr H. Sawalha   +2 more
wiley   +1 more source

Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies

MedComm, Volume 7, Issue 11, November 2026.
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang, Siwen Wu, Yusi Wang, Die Hu, Li Yang   +4 more
wiley   +1 more source

Temporal Trends in Janus Kinase Inhibitor (JAKi) Use Across Five European Countries: A DARWIN EU Network Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 11, November 2026.
ABSTRACT Introduction Janus kinase inhibitors (JAKi) are increasingly used for autoimmune conditions despite existing safety concerns. This study aims to estimate the incidence of new JAKi use over time and characterise users in Europe to support future safety studies.
Xihang Chen, Andrei Barbulescu, George Corby, Saeed Hayati, Annika Jodicke, Toni Lehtonen, Hedvig Marie Egeland Nordeng, Alexandra Pacurariu, Gabriel Sanfélix‐Gimeno, Nhung T. H. Trinh, Katia Verhamme, Dina Vojinovic, Daniel Prieto‐Alhambra, Amy Shuk‐Man Lam, Edward Burn   +14 more
wiley   +1 more source

Janus Kinase Inhibitor Use Among People With Inflammatory Disease in Australia

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 11, November 2026.
ABSTRACT Aim To describe Australian trends in JAKi uptake, where there are no restrictions on the sequence of their use in clinical practice. Methods We included all people aged 18 years and over initiating a JAKi between 1 October 2015 and 31 August 2022.
Claire T. Deakin, Michael O. Falster, Geoffrey O. Littlejohn, Peter Youssef, David Liew, Nicole L. Pratt, Sallie‐Anne Pearson   +6 more
wiley   +1 more source

Pantethine Restores Epidermal Homeostasis and Modulates Vesicle‐Associated Proteins in Psoriasis

Experimental Dermatology, Volume 35, Issue 11, November 2026.
Pantethine attenuates psoriasis‐like epidermal pathology in a full‐thickness 3D human skin model by modulating inflammatory, oxidative‐stress, differentiation and tissue‐remodelling responses, alongside changes in vesicle‐associated proteins. These findings support restoration of epidermal homeostasis, although direct effects on extracellular vesicles ...
Passanesh Sukphopetch, Kamonpan Fongsodsri, Pornanong Aramwit, Onrapak Reamtong, Tipparat Thiangtrongjit, Tapanee Kanjanapruthipong, Watcharamat Muangkaew, Sumate Ampawong   +7 more
wiley   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, Volume 65, Issue 11, Page 2362-2370, November 2026.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source

Beyond disease activity: patient-reported impact of disease states in psoriatic arthritis using PsAID-12 time-independent clustering. [PDF]

RMD Open
P G, I T, J W R B, G H K, Henkemans S V J S, M V, M R K, R B, J B, J H VK, P K, K V, L A K, M VO, J F, J J L.   +15 more
europepmc   +1 more source